


NJ Bio collaborates with Ajinomoto BioPharma to strengthen support for ADC development

April 2, 2026 | News

NJ Bio will integrate the AJICAP® platform into its discovery and development workflows



US-based NJ Bio, Inc., a leading provider of integrated drug discovery and development services and Japan's Ajinomoto BioPharma Services, a leading provider of biopharmaceutical manufacturing services and platform technologies, have announced a research collaboration to expand access to AJICAP™, Aji BioPharma's site-specific conjugation platform for NJ Bio's discovery-stage and early development clients.

This collaboration broadens NJ Bio's advanced antibody conjugation and linker capabilities, supporting the development of next-generation antibody–drug conjugates (ADCs) and other targeted therapeutics.

Through the collaboration, NJ Bio will integrate the AJICAP™ platform into its discovery and development workflows, offering clients a robust and highly reproducible approach for site-specific conjugation of cytotoxic and non-cytotoxic payloads to antibodies. AJICAP™ enables precise chemical modification at defined lysine residues without the need for antibody engineering, preserving antibody structure and functionality while improving pharmacokinetics, therapeutic index, and overall developability. The platform supports a range of stable, hydrophilic linker systems and is readily incorporated into drug discovery and development programs.

AJICAP™ technology is widely recognised for its scalability, consistency, and compatibility with standard antibody production processes. By integrating this platform, NJ Bio strengthens its position as a comprehensive partner for biopharmaceutical companies seeking end-to-end support, from early drug design and discovery through preclinical development.